𝗖𝗚-𝟬𝟰𝟭𝟲 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛: 𝗙𝗔𝗧 𝗟𝗢𝗦𝗦 𝗪𝗜𝗧𝗛𝗢𝗨𝗧 𝗠𝗨𝗦𝗖𝗟𝗘 𝗟𝗢𝗦𝗦 𝗘𝗫𝗣𝗟𝗔𝗜𝗡𝗘𝗗

Discover how CG-0416, a novel oral THR-β agonist, achieves high-quality fat loss while preserving muscle. Learn about its potential in obesity and metabolic liver disease treatment, synergy with GLP-1 therapies, and why it could reshape the weight-loss market.

Key Points Covered:

How CG-0416 targets liver metabolism, not appetite

Fat-first weight loss with minimal muscle loss

Synergy with GLP-1 drugs for enhanced results

Oral dosing for better adherence and patient convenience

Market potential in obesity and MASH/NASH

Subscribe for more updates on cutting-edge obesity and metabolic disease therapies.
#CG0416 #FatLoss #WeightLoss #ObesityTreatment #THRbeta #GLP1 #MusclePreservation #MetabolicHealth #OralTherapy #HealthInnovation

Видео 𝗖𝗚-𝟬𝟰𝟭𝟲 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛: 𝗙𝗔𝗧 𝗟𝗢𝗦𝗦 𝗪𝗜𝗧𝗛𝗢𝗨𝗧 𝗠𝗨𝗦𝗖𝗟𝗘 𝗟𝗢𝗦𝗦 𝗘𝗫𝗣𝗟𝗔𝗜𝗡𝗘𝗗 канала AI Biopharma Playbook